Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great post listen at 4.45 where DR P talks about going for
Basket Trial: Basket trials (or studies) test the effect of one drug on a single mutation in a variety of tumor types, at the same time. These studies also have the potential to greatly increase the number of patients who are eligible to receive certain drugs relative to other trials designs.
Where do you get 10 million?
Fortuno $ 35 M
JPG77 $ 35 M
SJacobs $ 26.4 M
Lorbas $ 22.3 M
Z_Smith $ 20 M
Misiu143 $ 20 M
Bored Lawyer $ 15 M
newrunner $50M
Do not forget this
Maraviroc can cause serious, life-threatening side effects. These include liver problems, skin reactions, and allergic reactions. An allergic reaction may happen before liver problems occur.[15] Official labeling of Selzentry has black box warning for hepatotoxicity.[1]
PRO140_CD 01 (NCT02175680) and PRO 140_CD 01-Extension (NCT02355184):
There were no drug-related serious side effects and no participants dropped out of the study because of a side effect. All of the reported side effects that were definitely or probably related to leronlimab were local injection site reactions of mild or moderate severity.9,10,14
Suvorov
This is fun seeing you squirm to try and save us from the SEC.
I do not ever recommend the stock on social media instead I direct them to a company that will provide help for them and maybe get them in trials.
Thank you so much LongPennypincher I bet if you go straight to Nadar he would be more than happy to have your wife helps us out. If you need help reaching him just let me know.
Longpennypincher
You are totally correct but we have to work together on this!
I tried the National Associations but guess what,
if we have a cure for anything they will be out of a job so remember to go after the PATIENT we are fighting both BP and the executive directors.
Social media is amazing! I look at Twitter, Facebook, Instagram, and Tripple Negative Breast cancer has pages with thousands of followers people trying to help each other but no one knows about Leronlimab (PRO 140)!
I just wish I could reach out to each one and say look we have hope for you.
https://www.healthcentral.com/slideshow/metastatic-breast-cancer-warning-signs?ap=825&pb=00462fbbf5b42a10b13c8bd4c939f1c67c&aid=00a0c2f6ffe54998c1c835b370d36637d5
EVERYONE SHOULD WATCH THIS INTERVIEW WITH NADAR
I THINK IT'S GREAT
Rock on Chump that's how you defend your million plus position thank you for your expert due diligence.
Finesand
Do you know how many shares have been sold in the last 5 years? It's 10 times the amount Paulson has
Cytodyn hired this Company to try and weed out the phantom Shorts I was told by this Company that we could have almost 100 million short. The OTCBB is not regulated and many market makers and DTC are making millions playing this illegal game. I think it's BS to think Paulson is selling. What will be interesting is if we are bought out can you imagine that many shares covering. They won't cover because it's phantom and nothing can make them cover.
I said no more on how we are being manipulated but yesterday was different.
Many have posted strange timing on orders.
Dear CYDY Investor Relations:
Here is your Buyins.net RegSHO Compliance Alert for February 27th, 2019. Our RegSHO Compliance Service helps to protect CYDY from short sellers and market makers that are violating the more stringent RegSHO market integrity provisions recently enacted. We are monitoring the trading activity in CYDY and here is today's report:
Total Trading Volume: 462103
Daily Short Volume: 422203
Avg. Price of Shorts Today: 0.518
Short %: 91.37
Volume at Offer: 295862
Buy%: 64.03
Volume at Bid: 166191
Sell%: 35.96
Shares Crossed: 50
Cross%: 0.01
Net Buying vs. Selling: 129671
Price Change: 0.0225
Friction Factor: 57631.55556
The above data is used to calculate if a fair market is being made in the shares of CYDY. Friction Factor determines if there is normal or abnormal behavior in the price action of the stock when compared to the buying vs. selling trading statistics. Today, your Friction Factor was 57631.55556. Here is how to understand Friction Factor:
1. If Friction Factor is positive, more buying than selling caused CYDY's price to rise
2. If Friction Factor is negative, more selling than buying caused CYDY's price to fall
3. If Friction Factor is 0, there was no discernable activity either way
4. If Friction Factor is abnormal, it means that more buying than selling caused the price to drop, which is evidence of manipulative activity. In some cases more selling than buying can cause the price to increase. While this is rare, it must be noted as well.
By signing up for our RegSHO Compliance Service, we will monitor your trading daily and identify short selling, illegal short selling, manipulative market maker activity and alert the media when a short squeeze begins and when forced buy-ins occur because we were able to get broker dealers, FINRA or the SEC to force �buy to covers� upon short sellers that have not located, borrowed and delivered shares shorted by T+3.
Here are our unique data sources:
1. Nightly Threshold Security Lists ("Naked Short Lists"): data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
2. Daily Size of Failures to Deliver ("Size of Naked Shorts on a day to day basis): directly from SEC
3. Daily Short Sales Times and Sales Data: data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
4. Brokerage firms that trades go through: data comes directly from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges
5. Names and positions of short sellers with assets under management exceeding $100 million: data will come directly from SEC
6. Blue Sheet Data Requests: We deal directly with FINRA and SEC to alert them as to which stocks and which brokerage firms SEC and FINRA need to investigate.
7. Trading Statistics and Friction Factor are based on data provided by all US stock exchanges and proprietary analysis of the activity.
The data we provide is extremely useful for CYDY for the following reasons:
1. Stop naked short selling in the company you are covering
2. Break the market maker hold on Level II box causing so much price friction
3. Our SqueezeTrigger Reports that cross newswires and are sent to our 720,000 users help break the rest of the shorts
4. Discourage new short sellers from shorting your stock
5. Stop the negative perception that dropping stock price places on normal day to day business operations
6. Combined all of these facets help to stop the daily drain that the short attacks have on the company.
Please call us for details.
Tom Ronk, RIA, CTA
Founder & CEO
Newport Beach, CA
tom@buyins.net
1-949-230-7680
https://wopr.buyins.net/
I agree but Fine does not seem to be so rude as some of the others and she is really way over most peoples head with her post. Sometimes I think one day she is a female and one day he is a man. It's very easy to put both on ignore.
Thank you Bulldog 88 Great post!!!!!!!
Want To enjoy this Board then put Suvorov,Grip it and Sip, EETROG on ignore
and enjoy the people who are positive.
Emergcy
What if the 100 million are short and have to cover, have you thought about that?
For those of you who want to take on NP he is an avid runner, 10th-degree black belt and does not drink. His only hobby is work! A very spiritual person.
I would consider just a nice handshake if you meet him.
t0m - if we find enough 1d10t5 selling this low now, yes (o8>
Related terms such as PEBKAC ("problem exists between keyboard and chair"), identity error or ID-10T/1D-10T error ("idiot error"), PICNIC ("problem in chair, not in computer"), IBM error ("idiot behind machine error") and other similar phrases are also used as slang in technical circles with derogatory meaning.
Wow, Bobby great find I am convinced that Pro140 is a gift to this man.
I am done talking about shorts
HOW ABOUT THIS
60 billion / 500 million =
one hundred twenty a share but what is share if we do 60 billion every year?
Private Jet
To take all of you to Vegas
The UPTICK Rule has nothing to do with the PINK or The OTCBB. It's is very corrupt and no one regulates it. Call the Tom guy at buyins and ask them. From what I understand Paulson was aware of the Naked Shorts and brought on this Company to help CYDY. FACT NOT THEORY WITH ALL DUE RESPECT!
It's not a person but DTC allowing firms like NITE to make millions manipulating the markets. This is why the OTCBB is dying
READ MY EARLIER POST PAULSON IS NOT SELLING ITS SHORTS
Tommy this is who is selling, it's all computer driven and when we hit .82 the reflection point the machines go crazy covering. .20 more cents and its game over for the shorts. Cytodyn has hired this Company to clean up the shorts. Call Tom below to ask him
Dear CYDY Investor Relations:
Here is your Buyins.net RegSHO Compliance Alert for January 3rd, 2019. Our RegSHO Compliance Service helps to protect CYDY from short sellers and market makers that are violating the more stringent RegSHO market integrity provisions recently enacted. We are monitoring the trading activity in CYDY and here is today's report:
Total Trading Volume: 192106
Daily Short Volume: 137205
Avg. Price of Shorts Today: 0.52
Short %: 71.42
Volume at Offer: 126756
Buy%: 65.98
Volume at Bid: 65350
Sell%: 34.02
Shares Crossed: 0
Cross%: 0
Net Buying vs. Selling: 61406
Price Change: 0.0492
Friction Factor: 12480.89431
The above data is used to calculate if a fair market is being made in the shares of CYDY. Friction Factor determines if there is normal or abnormal behavior in the price action of the stock when compared to the buying vs. selling trading statistics. Today, your Friction Factor was 12480.89431. Here is how to understand Friction Factor:
1. If Friction Factor is positive, more buying than selling caused CYDY's price to rise
2. If Friction Factor is negative, more selling than buying caused CYDY's price to fall
3. If Friction Factor is 0, there was no discernable activity either way
4. If Friction Factor is abnormal, it means that more buying than selling caused the price to drop, which is evidence of manipulative activity. In some cases more selling than buying can cause the price to increase. While this is rare, it must be noted as well.
By signing up for our RegSHO Compliance Service, we will monitor your trading daily and identify short selling, illegal short selling, manipulative market maker activity and alert the media when a short squeeze begins and when forced buy-ins occur because we were able to get broker dealers, FINRA or the SEC to force �buy to covers� upon short sellers that have not located, borrowed and delivered shares shorted by T+3.
Here are our unique data sources:
1. Nightly Threshold Security Lists ("Naked Short Lists"): data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
2. Daily Size of Failures to Deliver ("Size of Naked Shorts on a day to day basis): directly from SEC
3. Daily Short Sales Times and Sales Data: data comes from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges directly.
4. Brokerage firms that trades go through: data comes directly from AMEX, NASDAQ, NYSE, OTCBB, PINKSHEET exchanges
5. Names and positions of short sellers with assets under management exceeding $100 million: data will come directly from SEC
6. Blue Sheet Data Requests: We deal directly with FINRA and SEC to alert them as to which stocks and which brokerage firms SEC and FINRA need to investigate.
7. Trading Statistics and Friction Factor are based on data provided by all US stock exchanges and proprietary analysis of the activity.
The data we provide is extremely useful for CYDY for the following reasons:
1. Stop naked short selling in the company you are covering
2. Break the market maker hold on Level II box causing so much price friction
3. Our SqueezeTrigger Reports that cross newswires and are sent to our 720,000 users help break the rest of the shorts
4. Discourage new short sellers from shorting your stock
5. Stop the negative perception that dropping stock price places on normal day to day business operations
6. Combined all of these facets help to stop the daily drain that the short attacks have on the company.
Please call us for details.
Tom Ronk, RIA, CTA
Founder & CEO
Newport Beach, CA
tom@buyins.net
1-949-230-7680
https://wopr.buyins.net/
I have seen the NOBO reports and I have 4 million shares and I have not been listed. I know a few Trust's and they are not listed. You have only listed insiders. If someone on this Board knows someone with a large position with Paulson that has sold and kept the warrants, raise your hands.
For what it's worth is all Shorts no Paulson. In fact, it was Paulson that had Nadar hire
www.woprai.com to try and stop the naked shorts. This was nothing but a pure short attack moving shares from one account to another. Nite is the leader in this. Go back every day we had news the stock went down. That is not Paulson.
No, I cannot see it but what I see is a short attack by nite
CEO, talked with Stock Day's Everett Jolly.
Jolly started the interview by asking about CytoDyn Inc.'s flagship product, PRO 140.
"We do have a rolling submission with the FDA," explained Pourhassan. "So, we can submit as we get each module ready. By the end of the first quarter of 2019, we should have all of our BLA modules submitted to the FDA, if we do, our fast track designation for PRO 140 allows us to have accelerated approval which is 6 months."
PRO 140 is a humanized IgG4 monoclonal antibody that binds to CCR5, a cellular receptor that plays multiple roles with implications in HIV infection, tumor metastasis, and immune signaling.
"We hope to have our final approval in the fourth quarter of 2019," said Pourhassan.
Jolly then asked when Pourhassan thought PRO 140 would be available to the public. For our designated label for this study, he said his best estimate was 2020.
"Most biotech companies, when they finish the biologic application, they have an 85% chance to get approved. 9 out of 10 who don't get approved is because of the safety of the product. Our product has received fast track designation due to having great safety among all of the approved drugs," said Pourhassan.
Pourhassan also went into the hopes for the drug in the realm of HIV, he explained patients often experience complications with dosing for other HIV drugs.
"Our product is a simple, one dose per week and it's a simple injection," explained Pourhassan. "This is once per week, self-administered at home. They can forget about their HIV for the rest of the week."
Jolly then asked once it gets pass the FDA, is the company going to commercialize and he asked Pourhassan how big is the market they are trying to penetrate.
"The combination therapy with PRO 140 and other pills would give patients quite a lot of benefit, is $1.2 Billion dollars. This market size is verified by a 3rd party report. The other market size for our other phase 3 trial is about $4 billion per year. This market price is based on a low estimate of cost to patient of $24,000, per year," explained Pourhassan.
He said the market size is high. In order to commercialize the product, they will assemble a team to start the process. He said they are open to partnering with larger companies. He says they are looking a half-a-billion dollars in sales for 2020.
Jolly then turned the conversation to the company's work in cancer treatment. The company recently announced it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct a Phase 1b/2 clinical trial with PRO 140 (leronlimab) for treatment in breast cancer.
"The cancer only kills if it can metastasize," said Pourhassan. "If we show that PRO 140 can stop metastasis as we have in in-vitro studiesthen we have the potential to save many lives in triple negative breast cancer, and many other cancer, very quickly."
To hear the entire interview, listen to the Stock Day Podcast, here. https://upticknewswire.com/featured-interview-ceo-dr-nader-pourhassan-of-cytodyn-inc-otcqb-cydy-2/
About CytoDyn
CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication.
CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. More information is at www.cytodyn.com.
https://upticknewswire.com/featured-interview-ceo-dr-nader-pourhassan-of-cytodyn-inc-otcqb-cydy-2/
Read this
https://theintercept.com/2016/09/24/naked-shorts-cant-stay-naked-forever/
Once that CUSIP changes, the naked shorter has no apparent way to close out the naked short position. No stock under the old CUSIP number exists anymore; it all automatically converts to the new CUSIP.
Those trades can sit in the Obligation Warehouse forever, in theory. But the “aged fails” — essentially orphaned naked short transactions — remain on the naked shorter’s balance sheet as a liability to be paid later.
spongeboy Saturday, 01/09/10 07:40:42 PM
Re: TEX post# 278932 0
Post #
279029
of 346536
CUSIP CHANGE EXPOSES SHORTS
FROM OCT 1
Steve,
UBSS has traded 13% of all you volume over 1 billion shares. Today they are not on the bid or the ask. I called their trading desk and asked why and they said they are not allowed to comment to 3rd parties due to regulatory reasons. This market maker could be holding the FTDs putting you on RegSHO and would love to see you go out of business.
Rank Market Maker 2009 Volume % of Volume
1 Knight Equity Markets, L.P. 3,872,172,703 42
2 E*Trade Capital Markets Llc 1,221,151,096 13
3 UBS Securities LLC 1,176,368,331 13
--- On Wed, 9/30/09, steven moskowitz <symoskowitz@msn.com> wrote:
From: steven moskowitz <symoskowitz@msn.com>
Subject: Re: Steve - FW to your legal -this solves all our problems
Date: Wednesday, September 30, 2009, 9:02 AM
Are we back on sho list
Sent from my Verizon Wireless BlackBerry
-----Original Message-----
Date: Wed, 30 Sep 2009 13:01:33
To: <symoskowitz@msn.com>
Subject: Steve - FW to your legal -this solves all our problems
Steve,
Please read and reply
SPNGE has been on the SEC RegSho list for 47 stright days. This fact alone proves a massive FTD or naked short present. Some say one billion shares. If this is true a simple CUSIP number change would demolish shorts in 3 days? Here is an example from another firm:
Hard To Treat Diseases (HTDS) (FILING ) Caveat Emptor Rating
And CUSIP Change to Force Short Sellers To Cover
Toronto, Canada Sept. 15 - HTDS <http://www.htdsmedical.com/ <http://www.htdsmedical.com/>; <http://www.htdsmedical.com/ <http://www.htdsmedical.com/>; > > www.htdsmedical.com The issuers IR received the
following email from Pink Sheets where amongst other things Pink Sheets claims that it has
received complaints about improper promotions.
The company denies these allegations and finds these allegations disheartening and disingenuous
in view of the fact that the issuer is subject to a naked short and has began a vigilant effort to
have the shorts cover.
The company believes the short coverings started on September 14 as evidenced by the volume
and over 100% raise in its share per price values in a few hrs.
The issuer believes that a huge short position still exists on its security.
The current actions of Pink Sheets namely placing a "Skull and Bones" icon and ranking on
HTDS security may scare allot of new, novice and unsuspecting shareholders and will play into
the hands of the short sellers. Although the issuer can have the ranking removed usually with a
week, this is all the time in the world a short seller will need to cover the position as its army of
doomsday and dark propaganda posters pollute the Internet with their opinions.
HTDS and its advisors can not and will not allow its security to be systematically erased off the
books.
Effective today Sept. 15, 2009 HTDS will request a new CUSIP number from its transfer
agent. (See Foot note 1)
With the CUSIP number change does not mean there will be a change in the Company's name,
nor its symbol, and no consolidation of capital. This "time out' which usually lasts 3-4 days to
obtain the new CUSIP number will allow the company to prove to Pink Sheets that it had
nothing to do with the improper "Promotion", and to do the filings with Pink Sheets as per the
Pink Sheets email of September 14 2009. More importantly all broker dealers will have to
reconcile their accounts and any short positions must be covered.
It will also preserve the company equity and the last share price as recorded on close of
September 14 2009.
During this 3-4 day "time out" the company will provide further updates and news so to assist
shareholders with their positions and any short's not covered when the trading resumes. The
issuer and its advisers feel that this is the most prudent and best course to take to protect its
shareholders and its equity from the short seller's unscrupulous activities The issuer apologizes
for any inconvenience this has caused and assures its shareholders that the short term pain will be
well worth the long term gain.
TRY IT IT MAY SAVE SPNG
Finesand
If you were for real you would have never mentioned the short position. I have been in CYDY since 2011 and have many shares. I am really concerned that you would bring that up as a negative. I have been in the investment business for over 40 years and you concern me.
Chump is our new moderator. Thank you, Chump
I cannot wait to hear the rebuttal from Finesand on the interview that Chump posted. In case she missed it,
The Bio Report. Why an HIV Drug in Development Could Change How Cancer Is Treated
https://soundcloud.com/levine-media-group/why-an-hiv-drug-in-development-could-change-how-cancer-is-treated
Finesand move on to something else. Where do you get your facts?
I have said for years that we have a huge naked short position and it is huge, maybe over 100 million. Think about the last three years stock not going anywhere thanks dolphin0m for your post